The multi-target deal expands Zealand's metabolic pipeline with AI-designed multispecific proteins as obesity drug competition intensifies.

The RNAi-focused pact with Rona extends Roche's China deal streak and adds a novel target to its obesity R&D footprint.

The broader label clears a new patient group months ahead of the FDA deadline, lifting ImmunityBio shares.

The local launch undercuts rival GLP-1 prices as Korean regulators scrutinize obesity drug pricing and prescribing.

Pharma companies are challenging the mandatory international price benchmarking program in court.

The price cut comes as the White House weighs action on weight-loss drug costs and the obesity market reshapes spending.

The move trims Pfizer's oral obesity ambitions amid a crowded and competitive GLP-1 market.

The data supports Skyrizi's expanding role in inflammatory bowel disease and follows recent FDA news.

Regulators flagged a rare vision risk tied to GLP-1 use, adding to global scrutiny of the drug class.

The mid-stage failure removes a pipeline catalyst for the specialty drugmaker.

The multiple myeloma combination results could support a new regimen in relapsed disease.

The setback weighs on BioNTech's oncology pipeline beyond its COVID vaccine franchise.

The subgroup data could support Verastem's pancreatic cancer strategy despite prior competitor struggles.

The licensing deal adds early-stage oncology assets to Gilead's pipeline.

The mixed readout adds uncertainty to one of the company's late-stage programs.

Drugmakers object to broader price reductions that could pressure returns in Japan's market.

The first approval marks a regulatory milestone for Celcuity's oncology program.

The analyst note follows FDA approval of Ionis's rare-disease drug Tryngolza.